Vicore Appoints Leading Respiratory Medicine Developer Dr. Bertil Lindmark MD, PhD, as Chief Medical Officer

  • Vicore continues to strengthen its leadership in idiopathic pulmonary fibrosis (IPF) drug development by appointing Dr. Lindmark as its new Chief Medical Officer
  • Lindmark brings deep expertise in late-stage clinical development for respiratory diseases, having developed Symbicort and several other global respiratory brands
  • Appointment reflects Vicore’s advancement to late-stage development in IPF, following the interim phase 2a AIR data read-out showing potential for improving lung function

Read more…